中医杂志

[1]CELEBI S,ACIK Y,DEVECI SE,et al.Epidemiological features of irritable bowel syndrome in a Turkish urban society[J].J Gastroenterol Hepatol,2004,19(7):738-743.

[2]潘国宗,鲁素彩,柯美云,等.北京地区肠易激综合征的流行病学研究:一个整群、分层、随机的调查[J].中华流行病学杂志,2000,21(1):26-29.

[3]尉秀清,王锦辉.广州市居民肠易激综合征及功能性便秘的流行病学调查[J].中华内科杂志,2001,40(8):517-520.

[4]周建宁,侯晓华,刘南植,等.武汉地区消化内科就诊患者肠易激综合征的发病情况[J].胃肠病学,2006,11(6):356-358.

[5]张声生,李乾构,魏玮,等.肠易激综合征中医诊疗共识意见[J].中华中医药杂志,2010,25(7):1062-1065.

[6]BRIAN EA,FERMIN M,LIN C,et al.Bowel Disodrers[J].Gastroenterology,2016,150(5):1393-1407.

[7]姚欣,杨云生,赵卡冰,等.罗马III标准研究肠易激综合征临床特点及亚型[J].世界华人消化杂志,2008,16(5):563-566.

[8]DROSSMAN DA.Mutli-dimensional clinical profile(MD-CP)for functional gastrointestinal disorders[M].North Carolina:the Rome Foundation,2015.

[9]张正利,蔡淦.肠易激综合征中医论治溯源[J].中国中医基础医学杂志,2001,7(7):48-50.

[10]项柏康.重视肠易激综合征发病机理的研究及中医药治疗[J].浙江中医学院学报,2000,24(3):15-16.

[11]巩阳.王长洪教授从肝脾肾论治肠易激综合征的临床经验[J].中国中西医结合消化杂志,2008,17(3):24-25.

[12]王景秀,林平.肠易激综合征从肺论治浅析[J].浙江中医药大学学报,2011,35(1):9-11.

[13]陈晓敏,周福生.周福生教授治疗肠易激综合征验介绍[J].新中医,2006,38(6):10-11.

[14]苏晓兰,魏玮,林琳.魏玮教授论治腹泻型肠易激综合征经验[J].吉林中医药,2012,32(2):142-143.

[15]张北华,高蕊,李振华,等.中医药治疗肠易激综合征的专家经验挖掘分析[J].中国中西医结合杂志,2013,33(6):757-760.

[16]FOND G,LOUNDOU A,HAMDANI N,et al.Anxiety and depression comorbidities in irritable bowel syndrome(IBS):a systematic review and meta-analysis[J].Eur Arch Psychiatry Clin Neurosci,2014,264(8):651-660.

[17]李乾构,周学文,单兆伟.实用中医消化病学[M].北京:人民卫生出版社,2001:527-547.

[18]韩光研,孙建华.针灸治疗肠易激综合征取穴规律初探[J].辽宁中医药大学学报,2011,13(5):213-215.

[19]陈啓铭.肠三针结合灸百会治疗腹泻型肠易激综合征临床研究[D].广州:广州中医药大学,2011:1-29.

[20]覃泽珍.按摩与穴位注射疗法对肠易激综合征的临床疗效观察[J].按摩与康复医学,2011,2(6):47-48.

[21]董亮见.穴位埋线治疗便秘型肠易激综合征的临床研究[D].广州:广州中医药大学,2011:10-12.

[22]European Medicines Agency.Guideline on the Evaluationof Medicinal Products for the Treatment of Irritable BowelSyndrome[EB/OL].(2014-09-25)[2017-04-01].http://www.ema.eurpa.eu/docs/en_GB/document_library/Scientific_guildline/2014/09/wc500173457.pdf.

[23]US Department of Health and Human Services,Food and Drug Administration,Center for Drug Evaluation and Research(CDER).Guidance for Industry:Irritable Bowel Syndrome Clinical Evaluation of Drugs for Treatment[EB/OL].(2012-05-01)[2015-01-10].http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf.

[24]FRANCIS CY,MORRIS J,WHORWELLl PJ.The irritable bowel severity scoring system:a simple method of monitoring irritable bowel syndrome and its progress[J].Aliment Pharmacol Ther,1997,11(2):395-402.

[25]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:143.

[26]刘凤斌,王维琼.中医脾胃系疾病PRO量表理论结构模型的构建思路[J].广州中医药大学学报,2008,25(1):12-14.

[27]GROLL D,VANNER SJ,DEPEW WT,et al.The IBS-36:a new quality of life measure for irritable bowel syndrome[J].Am J Gastroenterol,2002,97(4):962-971.

[28]PATRICK DL,DROSSMAN DA,FREDERICK IO,et al.Quality of life in persons with irritable bowel syndrome:development and validation of a new measure[J].Dig Dis Sci,1998,43(2):400-411.

[29]MCINTOSH K,REED DE,SCHNEIDER T,et al.FODMAPs alter symptoms and the metabolome of patients with IBS:a randomised controlled trial[J].Gut,2017,66(7):1241-1251.